or Try an Advanced Search...

    Technical Analysis for TCRX - TScan Therapeutics, Inc.

    Grade Last Price % Change Price Change
    A 7.38 1.65% 0.12
    TCRX closed up 1.65 percent on Wednesday, April 24, 2024, on 41 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 7
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical TCRX trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Up 3 Days in a Row Strength 0.00%
    20 DMA Resistance Bearish 1.65%
    50 DMA Support Bullish 1.65%
    MACD Bullish Centerline Cross Bullish 1.65%
    Bollinger Band Squeeze Range Contraction 1.65%
    Doji - Bearish? Reversal 1.65%
    Older End-of-Day Signals for TCRX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 8 hours ago
    Possible Inside Day about 8 hours ago
    Up 3% about 8 hours ago
    Rose Above 20 DMA about 9 hours ago
    Up 2% about 9 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    TCRX Chart by TradingView
    Basic chart:

    Profile

    TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Life Sciences Immunology Solid Tumors Immune System Health Care Hematologic Malignancies Transplantation T Cell Tumors Of The Hematopoietic And Lymphoid Tissues Preclinical Stage Biopharmaceutical Therapies For The Treatment Of Patients With Cancer

    Is TCRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
    Apr 22 TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
    Apr 19 TScan Therapeutics Announces Closing of Upsized Public Offering
    Apr 17 TScan Therapeutics prices upsized stock offering to raise $150 million
    Apr 17 TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
    Apr 16 TScan Therapeutics announces launch of $125M proposed public offering
    Apr 16 TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
    Apr 16 TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
    Apr 8 TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
    Apr 2 TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
    See more TCRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.0
    52 Week Low 1.64
    Average Volume 220,899
    200-Day Moving Average 4.69
    50-Day Moving Average 7.08
    20-Day Moving Average 7.37
    10-Day Moving Average 7.26
    Average True Range 0.53
    RSI (14) 52.83
    ADX 19.18
    +DI 23.73
    -DI 17.88
    Chandelier Exit (Long, 3 ATRs) 7.41
    Chandelier Exit (Short, 3 ATRs) 8.17
    Upper Bollinger Bands 8.19
    Lower Bollinger Band 6.56
    Percent B (%b) 0.51
    BandWidth 22.07
    MACD Line 0.01
    MACD Signal Line 0.06
    MACD Histogram -0.0494
    Fundamentals Value
    Market Cap 321.38 Million
    Num Shares 43.5 Million
    EPS -2.02
    Price-to-Earnings (P/E) Ratio -3.65
    Price-to-Sales 16.41
    Price-to-Book 1.70
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.98
    Resistance 3 (R3) 7.96 7.73 7.88
    Resistance 2 (R2) 7.73 7.58 7.75 7.85
    Resistance 1 (R1) 7.56 7.49 7.65 7.58 7.81
    Pivot Point 7.33 7.33 7.38 7.35 7.33
    Support 1 (S1) 7.16 7.18 7.25 7.18 6.95
    Support 2 (S2) 6.93 7.09 6.95 6.91
    Support 3 (S3) 6.76 6.93 6.88
    Support 4 (S4) 6.78